


Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1 6 2 3	Attachment to Paper Number	1 5
Notice of References Cited	APPLICANT(S) Lori et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	S†	<u>Biochemicals/Organic Compounds for Research and Diagnostic Reagents</u> , Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
*	T†	Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," <i>Antiviral Chemistry & Chemotherapy</i> , 4(1), 55-63 (1993).
*	U†	Snyder et al. (I), "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," <i>Molecular Pharmacology</i> , 28(6), 574-580 (1985); see p. 578 in particular.
*	V	Licastro et al., "Inhibition of Polymerases- α and - β Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells," <i>Biochemical Biophysical Res. Comm.</i> , 132(3), 929-933 (November 15, 1985).
*	W†	Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," <i>AIDS Res. Human Retroviruses</i> , 6(9), 1139-1146 (1990).
*	X	R. S. Root-Bernstein(I), "AIDS IS More Than HIV: Part I," <i>Genetic Engineering News</i> , September 1, 1992, pp. 4-6.
*	Y	R. S. Root-Bernstein(II), "AIDS IS More Than HIV: Part II," <i>Genetic Engineering News</i> , September 15, 1992, pp. 4-5.
*	Z	"Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men," <i>Morbidity Mortality Weekly Rept.</i> , Vol. 30(25), Centers for Disease Control, July 3, 1981, pp. 305-308.
*	RA†	Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," <i>Science</i> , 220, 868-871 (1983).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE 05/01/03	page 2 of 5 ¥: Reference not presently available.
<p align="center">*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)</p>		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1623	Attachment to Paper Number 15
Notice of References Cited	APPLICANT(S) Lori et al.		

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	SA	Fauci (I), "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," <i>Science</i> , 239, 617-622 (February 1988).
*	TA	Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," <i>Science</i> , 262, 1011-1018 (November 12, 1993).
*	UA	Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," <i>Cell</i> , 61, 213-222 (April 20, 1990).
*	VA	Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection," <i>Science</i> , 254, 233-237 (October 18, 1991).
*	WA	Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell that Maintains Expression of CD4," <i>Science</i> , 245, 305-308 (July, 1989).
*	XA	Fox et al., "Lymphoid Germinal Centers Are Reservoirs of Human Immunodeficiency Virus Type 1 RNA," <i>Journal of Infectious Diseases</i> , 164, 1051-1057 (December, 1991).
*	YA	Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection," <i>New England Journal of Medicine</i> , 328(23), 1686-1695 (June 10, 1993).
*	ZA†	Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," <i>Journal of Virological Methods</i> , 20, 309-321 (1988).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. E. Crane	DATE 05/01/03	page 3 of 5 ¥: Reference not presently available.
<p>*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)</p>		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1 6 2 3	Attachment to Paper Number	1 5
Notice of References Cited	APPLICANT(S) Lori et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	RB	Yarchoan et al. , "Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," <i>New England Journal of Medicine</i> , 321(11), 726-738 (September 14, 1989).
*	SB†	Chow et al. , "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," <i>Nature</i> , 361, 650-654 (1993).
*	TB	Lori et al.(III) , "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," <i>Science</i> , 266, 801-805 (November 4, 1994).
*	UB†	Karlsson et al. , "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," <i>European Journal of Biochemistry</i> , 186, 689-694 (1989).
*	VB†	Marquez et al. , "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV," <i>Journal of Medicinal Chemistry</i> , 33(3), 978-985 (1990).
*	WB†	Snyder et al. (II) , "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in <u>DNA Repair et al. r and Its Inhibition</u> , <u>Nucleic Acids Symposium Series No. 13</u> , Collins et al. eds., IRL Press, Oxford, England, 1984, pp. 13-33.
*	XB	Vila et al. , "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]," <i>Lancet</i> , 350(9078), 635-636 (August 30, 1997).
*	YB	Schoofs , "The Berlin Patient," <u>The New York Times Magazine</u> , pp. 32-35, June 21, 1998.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE 05/01/03	page 4 of 5 ¥: Reference not presently available.
<p align="center">*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)</p>		


Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1 6 2 3	Attachment to Paper Number	1 5
Notice of References Cited	APPLICANT(S) Lori et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* ZB†	Balzarini, J. , "Effect of Antimetabolite Drugs of Nucleotide Metabolism on the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse Transcriptase Inhibitors," <i>Pharmacology and Therapeutics</i> , 87(2-3), 175-187 (2000).††
* RC†	Gao et al. (II) , "Enhancement by Hydroxyurea of the Anti-Human Immunodeficiency Virus Type 1 Potency of 2'- β -Fluoro-2',3'-dideoxyadenosine in Peripheral Blood Mononuclear Cells," <i>Biochemical Pharmacology</i> , 50(2), 274-276 (1995).††
SC†	Masood et al. , "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine," <i>Molecular Pharmacology</i> , 37, 590-596 (1990).
¥ TC	Hitchcock et al. , "Biochemical Pharmacology of 2'-Fluoro-2',3'-dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and Chemical Stability over 2',3'-Dideoxyadenosine," <i>Antiviral Chem. Chemother.</i> , 1, 319-327 (1990).
UC	Gao et al. (III) , "Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Investigations</i> , 91(5), 2326-2333 (May, 1993).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

EXAMINER L. E. Crane 	DATE 05/01/03	page 5 of 5 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/756,411	Group Art Unit 1 6 2 3	Attachment to Paper Number 1 5
Notice of References Cited	APPLICANT(S) Lori et al.		

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	4,708,818 A	11/24/87	Montagnier et al.	435	005.000	
*	B	5,026,687 A	06/25/91	Yarchoan et al.	514	045.000	
*	C	5,110,600 A	05/05/92	Green	424	450.000	
*	D	5,300,059 A	04/05/94	Rubinstein et al.	604	408.000	
*	E	5,521,161 A	05/28/96	Malley et al. (I)	514	045.000	
*	F	5,736,526 A	04/07/98	Malley et al. (II)	514	045.000	
*	G	5,736,527 A	04/07/98	Malley et al. (III)	514	045.000	
*	H	6,046,175 A	04/04/20	Lori et al. (I)	514	045.000	
*	I	6,093,702 A	07/25/00	Malley et al. (IV)	514	045.000	
*	J	6,194,390 B1	02/27/01	Lori et al. (II)	514	045.000	
*	K	6,093,702 A	07/25/00	Malley et al. (V)	514	045.000	

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	L	EP 0,206,497 A2	12/30/86	Europe(EPO)	Wellcome Fndtn	----	----		
*	M	WO87/01284 A1	03/12/87	World(WO/PCT)	US Dept. Commerce	----	----		

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Gao et al.(I), "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," <i>Proc. National Academy Sciences USA</i> , 90, 8925-8928 (October 1993).
---	---	---

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane <i>L. E. Crane</i>	DATE 05/01/03	page 1 of 5 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		